Intocell Stock

Intocell is a biotechnology company that develops antibody drug conjugate (ADC) platform technologies.

Sign up today and learn more about Intocell Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Intocell Stock

Intocell is a biotechnology company that develops an antibody-drug conjugate platform for the R&D and commercialization of biopharmaceuticals. Intocell creates protein-drug complexes, antibody-drug complexes, and other complexes with their own linkers and drugs.

Funding History

January 2016$1.0B
January 2021$34.0B

Management

Managing Director & CFO

Seo Young-seok

Advisor - Global Business Development

Dana Zhang

Founder & CEO

Park Tae-gyo

CHIEF DEVELOPMENT OFFICER

Jongsoo Kang

Managing Director & CSO

Sung-Joo Moon

CTO

Ryu Yo-seop

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo